+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hunter Syndrome Treatment Market 2019-2025

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129896
Global Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report, by Treatment (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others) and Forecast Period 2019-2025.

The global hunter syndrome treatment market is estimated to grow at a moderate CAGR during the forecast period. Hunter syndrome is a very rare genetic disorder caused by the malfunction of the enzyme, it happens due to the deficiency of the enzyme. Hunter syndrome is mainly seen in boys. According to the National MPS Society, 1 in 1,00,000 to 1 in 1,70,000 every male are affected by the hunter syndrome.

Innovative novel therapies in clinical trials and increasing R&D activities by major market players for the development of hunter syndrome treatment are the major two driving factors that are propelling the global hunter syndrome treatment market. For instance, in August 2018, ArmaGen received the US Orphan Drug Designation for AGT-184. It is an investigational enzyme replacement therapy (ERT) for the treatment of hunter syndrome treatment.

The global hunter syndrome treatment market is segmented based on treatment into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), and others (Gene Therapy, Bone Marrow Transplant, and Tonsillectomy). Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW.

The major players providing drugs of hunter syndrome treatment include Shire Plc. (Takeda Pharmaceutical Company), GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., ArmaGen Inc., Inventiva S.A., Denali Therapeutics Inc., and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale.

Few Recent Developments in the Market-
  • In November 2019, Bioasis announced the allowance of patent applications of xB3 platform in Japan, later in 2020, it allowed patent applications in the US and Europe.
  • In June 2019, Denali Therapeutics got approval from the US FDA for DNL310, it is an enzyme replacement therapy for patients with Hunter syndrome.

Research Methodology

The market study of the global hunter syndrome treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The Report Covers:
  • Comprehensive research methodology of the global hunter syndrome treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global hunter syndrome treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusions
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Takeda Pharmaceutical Company Overview SWOT Analysis Recent Developments
3.3.2. Clinigen Group PLC Overview SWOT Analysis Recent Developments
3.3.3. JCR Pharmaceuticals Co Ltd. Overview SWOT Analysis Recent Developments
3.3.4. RegenxBio Inc. Overview SWOT Analysis Recent Developments
3.3.5. ArmaGen, Inc. Overview SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Hunter Syndrome Treatment Market by Treatment
5.1.1. Enzyme Replacement Therapy (ERT)
5.1.2. Hematopoietic Stem Cell Transplant (HSCT)
5.1.3. Others ( Gene Therapy, Bone Marrow Transplant, Tonsillectomy)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. ArmaGen, Inc.
7.2. Bioasis Technologies, Inc.
7.3. Clinigen Group PLC
7.4. Denali Therapeutics, Inc.
7.5. EstevePharmaceuticals, S.A.
7.6. GC Pharma Corp.
7.7. Inventiva S.A.
7.8. JCR Pharmaceuticals Co., Ltd.
7.9. REGENXBIO, Inc.
7.10. Sangamo Therapeutics, Inc.
7.11. Shire Plc. (Takeda Pharmaceutical Company)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ArmaGen, Inc.
  • Bioasis Technologies, Inc.
  • Clinigen Group PLC
  • Denali Therapeutics, Inc.
  • EstevePharmaceuticals, S.A.
  • GC Pharma Corp.
  • Inventiva S.A.
  • JCR Pharmaceuticals Co., Ltd.
  • Sangamo Therapeutics, Inc.
  • Shire Plc. (Takeda Pharmaceutical Company)